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ABSTRACT
Background: Inflammatory myofibroblastic tumors (IMTs) are rare mesenchymal 
neoplasms that are composed of myofibroblastic cells accompanied by inflammatory 
infiltrate. We investigated the immune profiles of IMTs, including PD-L1 expression 
and proportion of CD8+ tumor-infiltrating lymphocytes (TILs), as well as its 
clinicopathological characteristics according to ALK gene rearrangement status. 
Methods: Twenty-eight IMTs from 25 patients were retrieved from our pathology 
files (2005–2015), and their clinicopathological parameters and outcomes were 
analyzed. Immunohistochemistry (IHC) was performed using whole-tissue sections 
to detect PD-L1 and CD8 expression, and fluorescent in situ hybridization (FISH) 
analysis and IHC were performed using tissue microarrays to identify rearrangements 
in the ALK, ROS1, and RET genes. 
Results: ALK rearrangement was observed in 11 cases (44.0%), and all cases 
exhibited diffuse cytoplasmic ALK expression during IHC. ROS1 or RET rearrangement 
was not detected using IHC or FISH. IMTs harboring ALK rearrangement (ALK-
positive) were located in the lungs (n = 7), genitourinary tract (n = 2), and mesentery 
(n = 1). The mean patient age was 33.2 years for ALK-positive IMTs and 53.1 years for 
ALK-negative IMTs. All patients with ALK-positive IMTs survived without recurrence 
or metastasis. IMTs with metastasis and/or recurrence were ALK-negative and 
exhibited elevated PD-L1 expression (positive tumor cells: 70.0% vs. 21.3%, P = 
0.023; H-score: 107.5 vs. 26.3, P = 0.005). In addition, ALK-negative IMTs had a more 
CD8+ TILs, compared to ALK-positive IMTs (23.3% vs. 8.9%, P = 0.027).
Conclusion: ALK-positive IMTs are characterized by younger age, well-defined 
margins, frequent involvement of the lung, and fewer CD8+ TILs. Greater PD-L1 
expression was observed in IMTs with tumor necrosis and metastasis/recurrence, 
which were also negative for ALK rearrangement. These results suggest that immune 
checkpoint inhibitors may be a novel option for treating patients with advanced IMT.
INTRODUCTION
Inflammatory myofibroblastic tumors (IMT) are rare 
but distinctive mesenchymal neoplasms that are composed 
of myofibroblastic cells accompanied by inflammatory 
infiltrate. These tumors can occur at any anatomical 
site, but typically involve the lung, soft tissue, and 
viscera of children and young adults [1]. Approximately 
half of IMTs harbor ALK gene rearrangement [2], and 
small subsets harbor kinase fusions, such as ROS1, 
PDGFRβ, and RET [3, 4]. These kinase fusions could be 
therapeutically targeted using tyrosine kinase inhibitors, 
as patients with IMTs harboring ALK rearrangements 
(ALK-positive) experienced sustained partial response 
to an ALK inhibitor (crizotinib) [5]. Immune checkpoint 
inhibitors have also recently provided substantial 
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therapeutic activity in various tumors that express PD-L1 
or have rich inflammatory components, such as malignant 
melanoma [6] and Hodgkin lymphoma [7]. The success 
of immunotherapy and interest in immune checkpoint 
inhibitors has led to research regarding PD-L1 and tumor-
infiltrating lymphocytes (TILs) in various tumors. As 
IMTs are characterized by TILs, we hypothesized that 
the immune checkpoint pathway would be involved in a 
subset of IMTs, which could have therapeutic implications 
for patients with advanced IMT. The present study aimed 
to evaluate PD-L1 expression and CD8+ TILs in IMTs, 
as well as the clinicopathological characteristics of IMTs 
according to ALK status.
RESULTS
Patient characteristics
Twenty-eight IMTs from 25 patients were examined, 
and their clinicopathological profiles are summarized in 
Table 1. The patients included 13 men and 12 women, 
with a mean age of 44.3 years (range: 0-76 years). One 
patient died because of the disease, 3 patients experienced 
local recurrence and/or metastasis, and 4 patients were 
lost to follow-up. The lung was the most common site of 
involvement (n = 8), and the genitourinary tract (n = 5) 
was the most common extrapulmonary site. Most patients 
(n = 23) underwent surgical resection and 2 patients were 
followed-up after the biopsy without further treatment. 
One patient received chemotherapy because of metastasis 
and 1 patient received radiotherapy because of local 
recurrence. 
Clinicopathological findings according to ALK 
status
Eleven cases (42.3%) had ALK rearrangement, and 
expression of ALK during the IHC was associated with 
the ALK break-apart FISH results. All ALK-positive IMTs 
exhibited diffuse granular cytoplasmic expression during 
the IHC (Figure 2A) and split signals during the FISH 
(Figure 2B). All cases were negative for ROS1 and RET 
during the IHC and subsequent FISH analysis. 
A comparison of the IMTs’ clinicopathological 
features according to ALK rearrangement status is shown 
in Table 2. Compared to ALK-negative IMTs, ALK-positive 
IMTs occurred at a younger age, were mostly located in 
the lungs, and were more circumscribed (Figure 3). All 
patients with ALK-positive IMTs underwent surgical 
resection and none of the patients experienced metastasis, 
recurrence, or death. There were no statistically significant 
differences in OS or DFS according to ALK status. 
However, ALK-positive IMTs tended to have superior OS 
and DFS (Supplementary Figure 1). 
Results from IHC for PD-L1 and CD8
PD-L1 positivity was observed in 10 of the 22 
available cases (45.5%). There were no differences in 
the clinicopathological features according to the PD-L1 
Figure 1: Nuclear features of inflammatory myofibroblastic tumors. A. Spindled/elongated cells are arranged in loose fascicles. 
B. There is a proliferation of plump epithelioid cells with prominent nucleoli that resemble ganglion cells. 
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results. In addition, there were no statistically significant 
differences in OS or DFS according to PD-L1 status, 
although PD-L1-positive IMTs tended to have poorer 
OS and DFS (Supplementary Figure 1). The rate of PD-
L1 positivity was not significantly different in the ALK-
positive and ALK-negative tumors (ALK-positive: 36.4% 
vs. ALK-negative: 54.5%, P = 0.392) (Table 2). The 
average proportion of CD8+ TILs was 18.5% among all 
IMTs. The proportion of CD8+ TILs was slightly higher in 
PD-L1-positive IMTs, compared to PD-L1-negative IMTs, 
Table 1: Clinicopathological profiles of the 25 patients with inflammatory myofibroblastic tumors
Case 
No.
Age 
(years) Sex Site
Size 
(cm)
ALK 
IHC
ALK 
FISH
Recurrence/
metastasis Treatment
FU 
period 
(mo)
Patient 
outcome
1 0 M Mesentery 8.7 + + No Surgical resection 52.5 NED
2 12 M Lung 3.5 + + No Surgical resection 69.5 NED
3 22 M Lung 0.6 + + No Surgical resection 108.9 NED
4 24 F Lung 7.5 + + No Surgical resection 53.8 NED
5 27 F Lung 2.7 + + No Surgical resection 21.8 NED
6 36 M Lung 6.0 + + No Surgical resection 6.9 NED
7 38 M Bladder 2.4 + + No Surgical resection 18.2 NED
8 45 F Lung 1.9 + + No Surgical resection 0.9 NED
9 47 M Lung 1.7 + + No Surgical resection 101.2 NED
10 54 F Stomach 1.5 + + No Surgical resection
11 60 M Ureter 1.3 + + No Surgical resection 91.5 NED
12 22 M Mediastinum 11.0 - - No Surgical resection 5.6 DUD
13 28 F Salivary gland 1.7 - - No Surgical resection 83.6 NED
14 40 M Mesentery 6.7 - - No Surgical resection 6.2 NA
15 44 F Kidney 5.3 - - No Surgical resection 118.3 NA
16 49 M Maxillary sinus 4.2 - - Yes Surgical resection (incomplete) 11.9 DAD
16a 49 M Lung Upto 9.5 - -
Metastasis, 
multiple (8mo)
Surgical resection 
and CTx
16b 49 M Maxillary sinus 6.1 - - Local recurrence (8mo)
Surgical resection 
(incomplete) and 
CTx
17 49 F Uterus 7.8 - - No Surgical resection
18 51 F Kidney 2.5 - - No Surgical resection 37.8 NED
19 55 M Kidney
2.5 
and 
2.3
- - Yes Bx & FU 17.2 AWD
19a 55 M Lung 3.0 - -
Metastasis, 
multiple 
(synchronously 
detected)
Surgical resection 17.2 AWD
20 57 M Mediastinum 8.5 - - No Surgical resection 18.5 NED
21 60 M Lung 0.8 - - No Surgical resection 63.3 NED
22 69 M Retroperitoneum 13.6 - - No Bx & FU 27.8 AWD
23 70 F Maxillary sinus 4.7 - - Local recurrence (1.0 mo)
Surgical resection 
RTx after local 
recurrence
35.7 NA
24 72 F Retroperitoneum 5.8 - - No Bx & FU 4.8 NA
25 76 F Mesentery 4.0 - - No Surgical resection 58.7 NED
IHC, immunohistochemical staining; FISH, fluorescent in situ hybridization; mo, month; M, male; F, female; +, positive; -, 
negative; postop., postoperative; Bx, biopsy; FU, follow-up; CTx, chemotherapy; RTx, radiotherapy; NA, not available; NED, 
no evidence of disease; AWD, alive with disease; DOD, died of disease; DUD, died of unrelated cause
Case 16 had metastatic (16a) and recurrent (16b) tumors. 
Case 19 had synchronously detected lung metastasis (19a).
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although the difference was not significant (19.7 ± 19.0% 
vs. 13.1 ± 10.8%, P = 0.316) (Figure 4A). ALK-negative 
IMTs had more CD8+ TILs, compared to ALK-positive 
IMTs (23.3% vs. 8.9% P = 0.027) (Figure 4B). 
There were four available IMTs from two patients, 
which included two primary IMTs arising in the maxillary 
sinus, one local recurrent tumor, and one metastatic lung 
tumor. These IMTs exhibited significant higher PD-L1 
proportions and H-scores in the tumor cells (Figure 5). 
IMTs with necrosis (n = 5) exhibited elevated PD-L1 
expression (56.0 ± 51.8% vs. 15.0 ± 28.4%, P = 0.029). 
DISCUSSION
The present study evaluated the clinicopathological 
characteristics of IMTs according to ALK status, and its 
relationships with PD-L1 expression and CD8+ TILs. We 
found that patients with metastasis/recurrence exhibited 
greater PD-L1 expression, and that ALK-negative IMTs 
had more CD8+ TILs, compared to ALK-positive tumors.
IMT is now thought to be a true neoplasm with 
intermediate biologic potential, as ALK rearrangement 
is now observed in approximately 50% of IMTs [2]. In 
the present study, ALK rearrangement was observed in 
44.0% of the cases, and ALK-positive IMTs occurred in 
younger patients, compared to ALK-negative cases, which 
is consistent with the findings of previous studies [4, 8, 9]. 
However, the lungs and the genitourinary tract were the 
most common sites of ALK-positive IMTs in our study, 
which is slightly different from the findings of previous 
studies [3, 8, 10]. For example, Western studies have most 
commonly found ALK-positive IMTs in the mesentery and 
lungs [3, 8], and the abdominal cavity was most common 
Table 2: Clinicopathological and histological features of primary inflammatory myofibroblastic tumors according to 
ALK status
ALK (−) (N = 14) ALK (+) (N = 11) P - value
Clinicopathological parameters
Sex (male) (%) 6 (42.9) 7 (63.6) 0.3021
Age (years, mean±SD) 53.0±16.1 33.2±18.2 0.0082
Tumor size (cm, mean±SD) 5.7±3.6 3.4±2.7 0.1062
Pulmonary location (%) 1 (7.1) 7 (63.6) 0.0073
Well-defined margins (%) 5 (35.7) 9 (81.8) 0.0421
Adjuvant treatment (%) 2 (14.3) 0 (0.0) 0.4873
Death (%) 1 (7.1) 0 (0.0) 0.0433
Overall survival (months, mean±SD) 35.2±34.5 50.7±38.2 0.2972
Metastasis/recurrence (%) 3 (21.4) 0 (0.0) 0.2303
Disease-free survival (months, mean±SD) 32.2±36.0 50.7±38.2 0.2272
Histomorphological parameters
Morphology of myofibroblastic cells 0.6043
 Spindle (%) 11 (78.6) 10 (90.9)
 Plump, epithelioid (%) 3 (21.4) 1 (9.1)
Nuclear atypia of myofibroblastic cells (%) 6 (46.2) 5 (45.5) 1.0003
Prominent nucleoli (%) 1 (7.1) 5 (45.5) 0.0613
Necrosis (%) 2 (14.3) 3 (27.3) 0.6233
PD-L1 positivity 4 (36.4) 6 (54.5) 0.3923
CD8+ TIL (%) 23.3±17.8 8.9±6.7 0.0272
ALK (-), Negative for ALK rearrangement; ALK (+), Positive for ALK rearrangement; SD, standard deviation; TIL, tumor 
infiltrating lymphocytes
1Chi-square test, 2T-test, 3Fisher’s exact test
Significant values in bold.
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in a Japanese cohort [10]. This difference may be related 
to the fact that we only examined Korean patients or a 
small sample size, and further studies are needed to 
validate our findings. 
Some specific histological features have been 
reported in lung adenocarcinomas with ALK or ROS1 
fusions, such as a mucinous cribriform pattern or solid 
growth pattern with signet ring cells [11, 12]. However, 
previous studies have failed to detect an association 
between histological results and molecular alterations in 
IMTs [4, 8]. In addition, histological features and ALK 
status have generally been reported to have no effect on 
prognosis [8]. We also did not detect any associations 
between histology or prognosis and ALK status, although 
ALK-positive IMTs tended to have a better prognosis. 
Yamamoto et al. have reported similar findings [10].
Although most IMTs have a relatively benign 
clinical course, a subset of patients experience local 
recurrence and metastasis. In these cases, patients with 
ALK-positive IMTs may benefit from treatment using 
crizotinib (an ALK inhibitor) [5]. Unlike patients with 
ALK-positive IMTs, patients with advanced ALK-negative 
tumors have no curative treatment options, and receive 
conventional palliative chemotherapy or radiotherapy. 
Figure 3: Imaging of inflammatory myofibroblastic tumors. A. Chest computed tomography reveals a tumor with smooth and 
well-defined margins in the lung parenchyma of a 12-year-old boy (Case 2). This tumor is positive for ALK rearrangement. B. Head 
magnetic resonance imaging reveals a lobulated irregular tumor arising in the sinusoidal space of a 70-year-old woman (Case 24). This 
tumor is negative for ALK rearrangement. Resection was incomplete during the first surgery, and the patient experienced local recurrence 
after 1 month.
Figure 2: Confirmation of ALK rearrangement using immunohistochemistry and fluorescent in situ hybridization 
analysis. A. All ALK-rearranged inflammatory myofibroblastic tumors display diffusely strong granular cytoplasmic expression of ALK 
during immunohistochemistry. B. Split signals confirm the presence of ALK rearrangement. 
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Immune checkpoint inhibitors have recently emerged 
as a new treatment option for somatic malignancies, 
including advanced non-small cell lung cancer [13, 14], 
advanced melanoma [6, 15], and head and neck squamous 
cell carcinoma [16]. PD-L1 expression is suggested as 
a predictive biomarker for responsiveness to anti-PD-1/
PD-L1 blockade therapy, and is associated with a high 
mutation burden and neoantigens [17, 18]. Interestingly, 
dense TILs, especially CD8+ cytotoxic T-cells, can predict 
treatment response among patients with melanoma who 
receive anti-PD-1 therapy [19]. TILs are a component 
of the tumor microenvironment and are thought to be 
recruited during the immune response to neoantigens that 
are produced by a tumor [20, 21]. In breast and colon 
cancers, dense TILs are a predictor of chemotherapy 
response and favorable outcomes [22, 23]. The US Food 
and Drug Administration has also recently approved 
immune checkpoint inhibitors that target CTLA-4 and 
PD-1.
Teng et al. have classified cancers into four groups 
based on their TILs and PD-L1 statuses [21]. In that 
classification, IMTs are considered type I (TIL+ and PD-
L1+) or type IV tumors (TIL+ and PD-L1-). As immune 
checkpoint blockade restores the function of cytotoxic 
T-cells, the presence of CD8+ TILs and high PD-L1 
expression are important factors to consider. Furthermore, 
IMTs are tumors with intermediate biologic potential, and 
are expected to have a low mutational burden, compared 
to highly aggressive carcinomas with a high mutational 
burden [17, 18]. In the present study, patients with 
aggressive IMTs exhibited greater PD-L1 expression 
and did not harbor ALK, ROS1, or RET rearrangements. 
Moreover, ALK-negative IMTs had more CD8+ TILs 
and tended to lead to poorer outcomes, compared to 
ALK-positive IMTs. However, only 3 patients in this 
study experienced metastasis and/or recurrence, and we 
were unable to adequately evaluate PD-L1 expression, 
CD8+ TILs, and ALK status. Previous studies showed the 
association between mutation burden and T-cell infiltration 
[24, 25]. CD8+ TILs reactive to clonal neoantigens were 
identified in early-stage tumor, and neoantigen specific 
CD8+T cells appeared to be enhanced by anti-PD-1 
therapy [26, 27]. Thus, it can be speculated that high 
numbers of CD8+ TILs in ALK-negative IMTs would 
imply the presence of more neoantigens, compared 
to ALK-positive IMT. Interestingly, greater PD-L1 
expression was observed in IMTs with tumor necrosis 
and metastasis/recurrence, which were also negative for 
ALK rearrangement. Thus, given that PD-L1 tended to be 
associated with a poorer prognosis, those cases appear to 
be potential candidates for immune checkpoint blockade 
therapy, especially ALK-negative IMTs that do not qualify 
for tyrosine kinase inhibitor treatment.
In the present study, we presumed that PD-L1 
expression and CD8+TILs as well as ALK status may be 
associated with biologic behavior of IMT, and expected 
that immune check point inhibitor might be beneficial 
to the patients with ALK-negative IMTs. However, there 
are several limitations in the present study. First, the 
number of included case was too small, as cases were 
obtained from a single institution, and only three patients 
experienced metastasis and/or recurrence. It was not 
adequate for appropriate statistical comparison, and also 
may be insufficient to conclude that ALK-negative IMT 
takes more aggressive clinical course than ALK-positive 
IMT. Second, there is still a concern that included ALK-
negative IMTs in this study might belong to unclassified 
low grade sarcoma or other tumor, although we thoroughly 
examined included cases with all available ancillary tests 
and excluded the differential diagnoses. Last but not least, 
one can have a question whether ALK-negative IMTs 
are tumors of higher mutation burden compared to ALK-
Figure 4: CD8-positive tumor infiltrating lymphocytes (TILs) in inflammatory myofibroblastic tumors (IMTs) based 
on PD-L1 A. and ALK B. status. The proportion of CD8-positive TILs was slightly higher in PD-L1-positive IMTs, compared to PD-L1-
negative IMTs (19.7 ± 19.0% vs. 13.1 ± 10.8%, P = 0.316) A.. ALK-negative IMTs had greater CD8-positive TIL infiltration, compared to 
ALK-positive IMTs (mean: 23.3% vs. 8.9% P = 0.027) B..
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positive tumors. Since there may be other explanations for 
T cell infiltration of the tumor, except mutation burden, 
further studies are needed to determine what mechanism 
is involved in T cell infiltration of IMT.
In conclusion, we identified distinct 
clinicopathological characteristics of IMTs according to 
ALK status among Korean patients. We also observed 
that aggressive IMTs had elevated PD-L1 expression 
and lacked ALK rearrangement, which might be useful 
for selecting patients for immune checkpoint blockade, 
although a large-scale study is needed to validate these 
findings. 
Figure 5: Higher PD-L1 expression in inflammatory myofibroblastic tumors with metastasis and recurrence. 
Inflammatory myofibroblastic tumors (IMTs) with recurrence and metastasis had significantly greater expression of PD-L1 according to 
proportion A. and H-score B.. C. A primary tumor that occurred in the maxilla of a 49-year-old man (Case 16). Lung metastasis developed 
5.3 months after the initial diagnosis. D. The metastatic lesion has tumor necrosis (inset) and increased tumor cellularity, with more severe 
nuclear atypia and prominent nucleoli, compared to the primary tumor. Diffuse expression of PD-L1 in primary E. and metastatic IMTs F.. 
NED: no evidence of disease.
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MATERIALS AND METHODS
This retrospective study was performed with 
approval of the institutional review board of Severance 
Hospital (4-2015-1081). 
Case selection
Twenty-eight IMTs from 25 patients were retrieved 
from our center’s pathology files (2005-2015). Twenty-
five samples were resected specimens and three samples 
were biopsied specimens. One patient had a renal IMT 
with lung metastasis. One patient had one recurrent IMT 
in maxillary sinus and one metastatic IMT in lung. 
The diagnosis of IMT was based on the 
morphological features and pathological criteria from 
the World Health Organization (WHO) classification 
of soft tissue tumors, as well as results from 
immunohistochemistry (IHC) and fluorescent in situ 
hybridization (FISH) [1]. Histologically, IMTs are 
composed of myofibroblastic and fibroblastic spindle 
cells with varying proportions of inflammatory infiltrate. 
Thus, we carefully excluded other possible spindle 
cell lesions, such as IgG4-related disease, spindle cell 
carcinoma, and dedifferentiated liposarcoma with IMT-
like features [28]. We comprehensively examined the 
patients’ clinical features and performed IgG4 and 
IgG IHC to exclude IgG4-related disease in cases with 
fibrosis and extensive plasma cell infiltration. Spindle 
cell carcinoma was excluded based on the results of 
cytokeratin IHC and precise histological examination. 
In cases of dedifferentiated liposarcoma with IMT-like 
features, thorough specimen sampling and histological 
identification of well-differentiated liposarcoma areas 
were performed. 
Clinicopathological analysis
The following clinicopathological parameters were 
recorded: age at diagnosis, sex, anatomical location, tumor 
size, tumor characteristics, treatment modality, date of 
death, metastasis, recurrence, overall survival (OS), and 
disease-free survival (DFS). Whole tumor sections from 
each case were reviewed by two experienced pathologists 
(YJC and HSS). Based on a previous report [1], the shape 
of the tumor cells was separately evaluated (spindle/
elongated vs. plump epithelioid, Figure 1) before assessing 
nuclear atypia, nucleolar prominence, and the presence of 
necrosis. 
Tissue microarray
Based on a retrospective review of the hematoxylin 
and eosin-stained slides, the most appropriate formalin-
fixed paraffin-embedded tumor tissue samples were 
retrieved and representative tumor areas were circled. Two 
3.0-mm tissue cores were obtained from the circled area 
of each paraffin block, and the cores were inserted into 6 
× 5 blocks.
Immunohistochemistry and fluorescent in situ 
hybridization for ALK, ROS1, and RET
IHC was performed using tissue microarray slides 
and antibodies against anaplastic lymphoma kinase (ALK; 
D5F3, 1:50; Cell Signaling Technology, Danvers, MA, 
USA), ROS1 (D4D6, 1:50; Cell Signaling), and RET (C-
19, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). The IHC results were obtained using the OptiView 
Detection Kit (Ventana Medical System, Tucson, AZ, 
USA). All cases were reviewed by two experienced 
pathologists (YJC and HSS). All cases were further 
analyzed to confirm rearrangement of ALK, ROS1, and/or 
RET using FISH and a break-apart probe for ALK (Abbott 
Molecular, Abbot Park, IL, USA), a ROS1 probe (Abbott 
Molecular), and a RET probe (ZytoVision, Bremerhaven, 
Germany) [29]. 
Immunohistochemistry for PD-L1 and CD8
IHC was performed using whole-tissue slides and 
antibodies against PD-L1 (SP263, rabbit monoclonal 
primary antibody; Ventana Medical System) and CD8 
(C8/144B, ready-to-use monoclonal mouse antibody, 
Agilent Technologies, Santa Clara, CA, USA). The IHC 
results were obtained using the OptiView Detection Kit 
(Ventana Medical System) and the UltraView Detection 
Kit (Ventana Medical System), respectively. The PD-L1 
IHC results were interpreted according to the methods 
of previous studies, and positive results were defined as 
≥1% of tumor cells with membranous staining [30, 31]. 
In addition to the proportion of PD-L1 positivity, the 
H-score was calculated for the PD-L1 staining. This score 
is calculated by multiplying the intensity value (0, 1, 2, 
or 3) by the extent of each staining intensity (%). The 
proportion of intratumoral CD8+ TILs was also recorded 
[31-33]. Necrotic areas were excluded from the scoring.
Statistical analysis
Data were reported as number and percentage or 
mean ± standard deviation. The analyses evaluated PD-L1 
expression, CD8+ TILs, clinicopathological parameters, 
and ALK status. The chi-square test and Fisher’s exact 
test were used for categorical parameters, and the t-test 
was used for continuous parameters. OS and DFS were 
evaluated using the Kaplan-Meier method and the log-
rank test. Statistical analyses were performed using IBM 
Oncotarget89473www.impactjournals.com/oncotarget
SPSS software (version 19.0; IBM Corp., Armonk, NY), 
and P-values of < 0.05 were considered statistically 
significant.
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